Pharmaceutical companies are attempting to solve unprecedented R&D and commercial challenges via business development, emphasizing cheaper, earlier-stage alliances and building up a base in emerging markets. An analysis of dealmaking trends from 2007 to 2010 shows big companies are embracing new kinds of partners, and shifting away from historic areas of interest to pursue hyper-specialty products and generics.
By Ellen Foster Licking and Christopher Morrison
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
